ASCO 2023 | Radiation and adjuvant nivolumab in HPV+ oropharynx cancer

Heath Devin Skinner, MD, PhD, Hillman Cancer Center, Pittsburgh, PA, discusses findings from the Phase II study (NCT03715946), which aimed to investigate treatment de-intensification for resected human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) by adding nivolumab to a reduced radiation therapy (RT) regimen. Eligible patients had high-risk factors and underwent transoral resection. Treatment consisted of accelerated fractionation RT with concurrent nivolumab, followed by adjuvant nivolumab for 6 months. The primary endpoint was progression-free survival (PFS). The study demonstrated that this de-intensified treatment approach combining nivolumab with RT was well-tolerated and showed favorable clinical outcomes for patients with high-risk, resected HPV+ OPSCC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.